PF 3716539Alternative Names: PF-03716539; PF-3716539
Latest Information Update: 12 Nov 2016
At a glance
- Originator ViiV Healthcare
- Developer Pfizer
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Viral infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Viral-infections(In volunteers) in Belgium (PO)
- 01 Oct 2008 Phase-I clinical trials in healthy volunteers in Belgium (PO)